Related Experiment Videos
Radiation-induced sarcoma: a challenge for the surgeon
Katja M J Thijssens1, Robert J van Ginkel, Albert J H Suurmeijer
1Department of Surgical Oncology, Groningen University Medical Centre, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.
Annals of Surgical Oncology
|April 14, 2005
Summary
Radiation-induced sarcoma (RIS) is aggressive and difficult to treat. Radical surgical resection offers the best chance for improved survival, though the overall prognosis for patients with RIS remains poor.
Area of Science:
- Oncology
- Surgical Oncology
- Sarcoma Research
Background:
- Radiation-induced sarcoma (RIS) presents a significant challenge in cancer treatment.
- Understanding RIS characteristics, outcomes, and prognostic factors is crucial for improving patient care.
Purpose of the Study:
- To define the disease process, characteristics, and outcomes of radiation-induced sarcoma (RIS).
- To identify potential determinants of outcome in patients diagnosed with RIS.
Main Methods:
- Retrospective analysis of 27 patients diagnosed with RIS between 1978 and 2003.
- Histological classification of RIS, including undifferentiated high-grade pleomorphic sarcomas and angiosarcomas.
- Evaluation of surgical resection radicality (R0, R1, R2, RX) and its impact on outcomes.
Main Results:
- The 5-year disease-free and overall survival rates were 27% and 30%, respectively.
- Local failure occurred in 54% of patients following R0 resection, with a 41% distant failure rate.
- Patients achieving R0 resection demonstrated significantly better survival rates compared to those with incomplete resection or no surgery.
Conclusions:
- Radiation-induced sarcomas are aggressive malignancies with high rates of local recurrence and distant metastasis.
- Radical surgical resection is the primary treatment modality offering the best chance for improved survival in RIS patients.
- Despite aggressive treatment, the overall prognosis for radiation-induced sarcoma remains poor, highlighting the need for further research and therapeutic advancements.